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Is Mitral Valve Physiology Moving From Global to Local?*Javier Sanz, MD,y Jonathan W. Weinsaft, MDzM itral regurgitation (MR) affects nearly 2million Americans with coronary arterydisease, conferring an increased risk of
heart failure, arrhythmia, and death. Commonly
referred to as ischemic mitral regurgitation (iMR),
this condition has generally been attributed to papil-
lary muscle displacement, leaﬂet tethering, and
annular dilation in the setting of myocardial infarc-
tion. Treatment is challenging. As recently shown in
a National Institutes of Health–sponsored trial, iMR re-
curs in approximately one-third of patients undergo-
ing mitral annuloplasty (1). Traditional cardiac
remodeling indexes provide limited value for predict-
ing iMR progression and therapeutic response. For
example, left ventricular (LV) chamber dimensions
can be similar among patients in whom iMR recurs or
improves after surgical intervention. Other markers
such as annular diameter are nonspeciﬁc for different
causes of mitral valve incompetence and thereby pro-
vide limited utility for developing mechanistically
guided therapies to treat underlying causes of iMR.SEE PAGE 1867In this issue of the Journal, Kalra et al. (2) examine
the impact on iMR of interpapillary muscle distance
(IPMD) shortening, driven by the hypothesis that,
rather than global LV size, an increase in IPMD
secondary to localized myocardial dysfunction is a*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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disclose.primary determinant of iMR. To do so, parallel
studies of iMR physiology were performed in clini-
cal patients, laboratory animals, and computational
models. Among patients (N ¼ 67), cardiac magnetic
resonance (CMR) was used to assess cardiac remod-
eling, infarct extent, and iMR severity. IPMD short-
ening from end-diastole to end-systole, measured as
the diameter between the anterolateral and poster-
omedial papillary muscles in the midventricular short
axis, was decreased among patients with moderate or
severe iMR (regurgitant fraction $30%) compared
with those without (9.6  2.8 mm vs. 11.5  3.4 mm;
p ¼ 0.02), despite similar end-diastolic IPMD and
global LV size and function. Reduced IPMD short-
ening directly correlated with infarct transmurality
and hypocontractility in LV myocardium underlying
the papillary muscles.
In the second set of experiments, iMR was assessed
by echocardiography 1 week after targeted obtuse
marginal branch occlusions in swine to create either
subpapillary infarctions (involving myocardium sub-
tending the papillary muscles) or nonpapillary in-
farctions (involving nearby myocardium but not the
papillary insertion). Advanced iMR consistently
developed in swine with subpapillary infarctions
(regurgitant fraction: 30.4  9.3%), whereas iMR did
not develop in those with nonpapillary infarctions
(10.7  3.5%; p < 0.001). Although the swine model
implies reduced IPMD shortening only in subpapillary
infarcts, the actual IPMD was not reported. Moreover,
although pathology specimens were studied, detailed
descriptions of infarct location, size, and trans-
murality were not provided.
To further test the signiﬁcance of IPMD shortening,
the investigators employed a computational model in
which LV and papillary remodeling indices were
modiﬁed and related to resultant change in mitral
regurgitant oriﬁce. Consistent with their previous
results, reduced IPMD shortening greatly affected
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1881mitral valve integrity: mitral oriﬁce size increased
with impaired IPMD reduction and mitral annular
dilation, but did not differ further with the addition
of global LV dilation. Conversely, LV dilation alone
only slightly increased the mitral oriﬁce area. Of note,
the magnitude of IPMD shortening (or LV dilation)
entered into this model was not speciﬁed by the
authors, raising the question of whether the compu-
tational simulations paralleled physiological range of
values observed in patients.
Taken together, the results of this comprehensive
multiparametric study provide further insight into
mechanisms responsible for iMR, particularly with
respect to papillary muscle–related geometry and
function. These ﬁndings add to a growing body of
literature demonstrating that a key determinant of iMR
is localized LV injury to the myocardium subtending
papillary muscle insertion and that the extent of
papillary dysfunction parallels that of the adjacent LV
wall. Clinical studies showed increased iMR preva-
lence after inferior and lateral wall infarcts (3,4). Pre-
vious animal models also demonstrated iMR to result
from infarction in LV myocardium underlying the
papillary muscles (5,6). More recently, CMR studies
conﬁrmed a similar independent association of infarct
location with iMR, even after controlling for global LV
remodeling indexes (7,8). Hypokinesis in these myo-
cardial territories is expected to reduce IPMD short-
ening and lead to increased leaﬂet tethering. Indeed,
the current results provide convincing data that IPMD
shortening—a straightforward, quantiﬁable index on
multiple cardiac imaging modalities—may affect iMR
to a greater extent than global LV remodeling. This is in
line with the ﬁndings of Delgado et al. (9) who, using
cardiac computed tomography in 67 heart failure
patients, demonstrated increased systolic IPMD in
those with moderate to severe MR, although LV vol-
umes did not differ. Fernandez-Golﬁn et al. (10) also
found that, apart from LV dimensions, both diastolic
and systolic CMR-based IPMDdiffered among ischemic
patients (n ¼ 45) with and without signiﬁcant iMR.
Combined, these data suggest that impaired IMPD
shortening may be associated with iMR in patients
with normal LV size, as well as in patients with
advanced LV dilation, with iMR in both cases stem-
ming from a common nidus of regional injury in LV
myocardium responsible for mitral valve closure.
From a physiological standpoint, whether papillary
muscle dysfunction itself is a primary determinant of
iMR or a passive manifestation of underlying LV wall
injury is still uncertain. Previous studies in both
experimental animals and humans suggest the latter.
Using a canine model of progressive coronary ﬂow
reduction, Matsuzaki et al. (5) found that papillarydysfunction alone was insufﬁcient to cause MR,
which was instead associated with LV lateral wall
hypokinesis. Messas et al. (6) performed targeted
coronary occlusion in a sheep model and found
that LV inferobasal ischemia produced MR, whereas
the addition of papillary ischemia paradoxically
decreased MR by reducing leaﬂet tethering and
improving valve coaptation. In the setting of local-
ized inferobasal remodeling (i.e., aneurysmal dila-
tion), papillary muscle dysfunction can attenuate
MR via decreased longitudinal contraction, resulting
in reduced leaﬂet tethering (11). Consistent with this,
in 2 separate CMR studies in post-infarct patients,
papillary muscle infarction had no impact on the
presence or severity of iMR (7,12). These previous
studies demonstrate that the mechanisms by which
papillary muscle involvement attenuates or exacer-
bates MR strongly depend on regional remodeling,
as well as infarction in the adjacent LV wall.
Different infarct sites and geometries may predomi-
nantly cause apical papillary muscle(s) displacement
(increasing tethering), reduced lateral contraction
(also increasing tethering), and/or direct dysfunction
of the papillary muscle (reducing tethering). Unfor-
tunately, data concerning papillary muscle infarction
on CMR was not presented in the current study.
Additionally, although IPMD shortening correlated
both with underlying LV infarction and iMR, the
independence (or lack thereof) of the association
between regional dyskinesis/infarct and IPMD in
relation to iMR was not tested.
Applied clinically, the ﬁndings of this study further
support that imaging approaches for iMR should be
tailored for assessment of mitral apparatus physi-
ology rather than global indexes of cardiac chamber
remodeling. Yet LV and annular size remain impor-
tant, as demonstrated by the authors’ computational
model, where increases in both structures with pre-
served IPMD shortening still resulted in signiﬁcant
MR. These data also emphasize the need for treat-
ment strategies that target underlying mechanisms of
iMR rather than the ﬁnal common endpoint of
valvular regurgitation itself. To this end, papillary
muscle repositioning and LV infarct plication tech-
niques have been tested in pilot studies (13,14). Mitral
annular support techniques are also being reﬁned to
better address regional impairments in mitral valve
integrity. Can IPMD shortening be used as a marker to
discern MR etiology and guide application of such
emerging therapeutic strategies? Further studies to
test the reproducibility and discriminatory capability
of this index to differentiate iMR from other etiologies
of mitral valve incompetence are certainly warranted.
Research is also necessary to test whether IPMD
Sanz and Weinsaft J A C C V O L . 6 4 , N O . 1 8 , 2 0 1 4
Moving From Global to Local? N O V E M B E R 4 , 2 0 1 4 : 1 8 8 0 – 2
1882yields superior predictive value to more complex in-
dexes (i.e., LV infarct distribution) with respect to
iMR progression and therapeutic response. Moreover,
as iMR can result from several different structural
determinants, it remains uncertain whether the
causal substrate for impaired IPMD shortening (i.e.,
ischemia vs. infarction) affects its predictive utility,
as well as how global and/or regional LV remodeling
inﬂuence the complex interaction between altered
papillary muscle function and iMR. The current studyprovides a valuable proof-of-concept as to IPMD’s
potential utility as a straightforward index, while
more broadly emphasizing localized myocardial
dysfunction as a key determinant of iMR.
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